Wedbush Cuts Earnings Estimates for Astria Therapeutics

Astria Therapeutics, Inc. (NASDAQ:ATXS - Free Report) - Analysts at Wedbush reduced their Q1 2025 EPS estimates for shares of Astria Therapeutics in a research report issued to clients and investors on Wednesday, March 12th. Wedbush analyst L. Chico now forecasts that the biotechnology company will post earnings of ($0.46) per share for the quarter, down from their previous forecast of ($0.40). Wedbush currently has a "Outperform" rating and a $28.00 price target on the stock. The consensus estimate for Astria Therapeutics' current full-year earnings is ($1.65) per share. Wedbush also issued estimates for Astria Therapeutics' Q2 2025 earnings at ($0.47) EPS, Q3 2025 earnings at ($0.48) EPS, Q4 2025 earnings at ($0.48) EPS, FY2025 earnings at ($1.88) EPS, FY2026 earnings at ($1.93) EPS, FY2027 earnings at ($2.22) EPS, FY2028 earnings at ($1.26) EPS and FY2029 earnings at $2.40 EPS.

Other research analysts have also issued research reports about the stock. HC Wainwright restated a "buy" rating and issued a $16.00 price target on shares of Astria Therapeutics in a report on Tuesday, March 11th. JMP Securities initiated coverage on shares of Astria Therapeutics in a report on Friday, January 31st. They issued an "outperform" rating and a $26.00 price target on the stock. Finally, Citizens Jmp raised shares of Astria Therapeutics to a "strong-buy" rating in a research report on Friday, January 31st. Six research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Buy" and a consensus target price of $26.67.

Remove Ads

Astria Therapeutics Stock Up 0.2 %

Shares of ATXS stock traded up $0.01 during trading hours on Friday, hitting $6.49. 368,454 shares of the company were exchanged, compared to its average volume of 453,733. The firm has a market cap of $366.26 million, a PE ratio of -3.11 and a beta of 0.69. Astria Therapeutics has a 1 year low of $5.73 and a 1 year high of $16.90. The firm has a fifty day moving average of $7.10 and a 200 day moving average of $9.46.

Astria Therapeutics (NASDAQ:ATXS - Get Free Report) last released its quarterly earnings results on Tuesday, March 11th. The biotechnology company reported ($0.44) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.01.

Institutional Investors Weigh In On Astria Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. KLP Kapitalforvaltning AS bought a new stake in Astria Therapeutics in the fourth quarter valued at $41,000. Tower Research Capital LLC TRC lifted its stake in Astria Therapeutics by 109.2% in the fourth quarter. Tower Research Capital LLC TRC now owns 5,299 shares of the biotechnology company's stock valued at $47,000 after buying an additional 2,766 shares during the last quarter. BNP Paribas Financial Markets bought a new stake in Astria Therapeutics in the fourth quarter valued at $50,000. Virtus ETF Advisers LLC bought a new stake in shares of Astria Therapeutics during the fourth quarter valued at about $65,000. Finally, Teacher Retirement System of Texas bought a new stake in shares of Astria Therapeutics during the fourth quarter valued at about $91,000. 98.98% of the stock is currently owned by institutional investors.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.